Post-Transplant Cyclophosphamide Is Associated with Improved Clinical Outcomes in HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation

MLA

Jimenez, Antonio M., et al. “Post-Transplant Cyclophosphamide Is Associated with Improved Clinical Outcomes in HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation.” Blood, vol. 138, no. 1, Number 1 Supplement 1, Nov. 2021, p. 1814. EBSCOhost, https://doi.org/10.1182/blood-2021-150714.

APA

Jimenez, A. M., Perales, M.-A., Devlin, S. M., Lekakis, L. J., Sauter, C. S., Pereira, D., Beitinjaneh, A., Brown, S., Wang, T., Ponce, D. M., Goodman, M. S., Chinapen, S., Komanduri, K. V., & Shaffer, B. C. (2021). Post-Transplant Cyclophosphamide Is Associated with Improved Clinical Outcomes in HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation. Blood, 138(1, Number 1 Supplement 1), 1814. https://doi.org/10.1182/blood-2021-150714

Chicago

Jimenez, Antonio M., Miguel-Angel Perales, Sean M Devlin, Lazaros J. Lekakis, Craig S. Sauter, Denise Pereira, Amer Beitinjaneh, et al. 2021. “Post-Transplant Cyclophosphamide Is Associated with Improved Clinical Outcomes in HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation.” Blood 138 (1, Number 1 Supplement 1): 1814. doi:10.1182/blood-2021-150714.